Javier López Jiménez
YOU?
Author Swipe
View article: 158 | EPCORE DLBCL‐3: FIXED‐DURATION EPCORITAMAB MONOTHERAPY IN OLDER (≥ 75 Y), ANTHRACYCLINE‐INELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED LARGE B‐CELL LYMPHOMA (LBCL)
158 | EPCORE DLBCL‐3: FIXED‐DURATION EPCORITAMAB MONOTHERAPY IN OLDER (≥ 75 Y), ANTHRACYCLINE‐INELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED LARGE B‐CELL LYMPHOMA (LBCL) Open
View article: Correction: Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal study
Correction: Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal study Open
View article: Combination of disease burden before allogeneic transplantation and early post-transplant minimal residual disease predicts survival in patients with acute myeloid leukemia
Combination of disease burden before allogeneic transplantation and early post-transplant minimal residual disease predicts survival in patients with acute myeloid leukemia Open
View article: Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal study
Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal study Open
View article: Adapting a mobile TB screening unit to provide integrated screening services and linkage to primary care
Adapting a mobile TB screening unit to provide integrated screening services and linkage to primary care Open
OBJECTIVEWe adapted a mobile TB screening unit to create an integrated screening program for noncommunicable diseases and TB, using community health worker (CHW) navigators to support linkage to care. We piloted the model in underserved co…
View article: Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia
Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia Open
Background The measurement of minimal residual disease (MRD) by multiparametric flow cytometry (MFC) before hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) is a powerful prognostic factor. The i…
View article: Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir
Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir Open
Background Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy of maribavir with fewer treatment-limiting toxicitie…
View article: POSTER: ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
POSTER: ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL Open
View article: The casts of Pompeii: Post-depositional methodological insights
The casts of Pompeii: Post-depositional methodological insights Open
The casts of Pompeii bear witness to the people who died during the Vesuvius 79 AD eruption. However, studies on the cause of death of these victims have not been conclusive. A previous important step is the understanding of the post-depos…
View article: Gamificación en el proceso de la enseñanza de los idiomas.
Gamificación en el proceso de la enseñanza de los idiomas. Open
El objetivo de esta investigación fue implementar la gamificación como herramienta de apoyo en el Colegio de Estudios Generales y de Servicios (CEGES) año escolar 2022-2023. Esta investigación asume el enfoque cualitativo, la investigación…
View article: Peripheral T‐cell lymphoma with a T follicular‐helper phenotype: A different entity? Results of the Spanish <scp>Real‐T</scp> study
Peripheral T‐cell lymphoma with a T follicular‐helper phenotype: A different entity? Results of the Spanish <span>Real‐T</span> study Open
Summary Nodal peripheral T‐cell lymphoma (PTCL) with a T follicular helper phenotype (PTCL‐TFH) is a new type of PTCL. We aimed to define its clinical characteristics and prognosis compared to PTCL not otherwise specified (PTCL‐NOS) and an…
View article: FIVE‐YEAR UPDATE OF THE FIRST‐LINE IMCL‐2015 GELTAMO STUDY. PROLONGED MOLECULAR AND CLINICAL RESPONSES WERE OBSERVED AFTER MRD‐DRIVEN IBRUTINIB DISCONTINUATION
FIVE‐YEAR UPDATE OF THE FIRST‐LINE IMCL‐2015 GELTAMO STUDY. PROLONGED MOLECULAR AND CLINICAL RESPONSES WERE OBSERVED AFTER MRD‐DRIVEN IBRUTINIB DISCONTINUATION Open
Introduction: A frontline tailored treatment for indolent clinical forms of mantle cell lymphoma (MCL) with ibrutinib in combination with rituximab was evaluated. A high rate of complete remissions (CR) with undetectable minimal residual d…
View article: Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Table from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Data from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Data from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous ovarian cancer (HGSOC) and for breast, prostate, and pancreatic cancers (PaC) harboring genetic alterations impairing homologous recombination repair (HRR…
View article: Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Table from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Figure from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Data from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Data from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Data from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Data from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Data from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Data from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Figure from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Figure from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Table from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Table from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Data from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Data from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous ovarian cancer (HGSOC) and for breast, prostate, and pancreatic cancers (PaC) harboring genetic alterations impairing homologous recombination repair (HRR…
View article: Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Figure from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Table from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Table from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Table from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Figure from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Supplementary Figure from Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification Open
Supplementary Figure from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
View article: A Symmetry-Based Unscented Particle Filter for State Estimation of a Ballistic Vehicle
A Symmetry-Based Unscented Particle Filter for State Estimation of a Ballistic Vehicle Open
The problem of state estimation for vehicles when an initial fix is highly uncertain and/or the number of sensors is not sufficient (and changes with time) is very relevant for both aircraft and spacecraft navigation. This work proposes a …
View article: Analysis of Immunological and Clinical Response to Vaccination Against Sars-COV-2 in Patients with Chronic Myeloid Leukemia
Analysis of Immunological and Clinical Response to Vaccination Against Sars-COV-2 in Patients with Chronic Myeloid Leukemia Open
Background: Patients with oncohematological malignancies have been excluded from the clinical trials in which the vaccines against COVID-19 were approved. Although there are some studies that have evaluated the immunologic and clinical res…